drugset / Trial / NCT03710915

A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

NCT03710915 ↗

Phase 1 Terminated 3 enrolled HitGen Inc.
NaSequentialOpen-labelTreatment

Summary

This study is designed to evaluate the tolerability and safety of HG146 capsule in patients with multiple myeloma.

Timeline

Start
2019-01-12
Primary completion
2022-09-28
Completion
2023-06-28

Outcome

Outcome not reported

Stopped: “Company decision”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject HG146 Unknown 5 mg Oral
Subject HG146 Unknown 10 mg Oral
Subject HG146 Unknown 15 mg Oral
Subject HG146 Unknown 20 mg Oral